Colombian congressman Hernando José Padaui has submitted a proposal before the House of Representatives, dubbed the ‘Anti-Ibuprofen Law’, which would force public medicine providers and insurance to provide only originally branded medication to patients, banning the use of generic alternatives. The proposal has been soundly critcized by Colombia’s pharmaceutical sector, with billions of dollars at stake.
Congressman Padaui has defended his proposal, claiming it seeks to boost competition and break up the monopolies of a few pharmaceuticals by promoting the development of new patent drugs and increasing both supply and demand, helping to offset foreseen rises to public spending as a result.
Cesar Burgos Alarcón, president of the Colombian Association of Scientific Societies, expressed his concern over the proposal’s principal mechanism, which would restrict doctors’ ability to prescribe generic alternatives to patients, justified by an assumed reduction in quality when compared to original formulas as the tradeoff for lower prices. “We believe that, beyond the economic impact that could be felt, the fundamental fact lies in the placement of constraints to the autonomy of medical practitioners to prescribe medication, as enshrined in the Legal Statutes, as an element which guarantees the basic right to healthcare.”
Full Content: Vanguardia
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI